Medicine and Health Sciences Commons^™

Data-Driven Neuroanatomical Subtypes In Various Stages Of Schizophrenia: Linking Cortical Thickness, Glutamate, And Language Functioning, Liangbing Liang

Electronic Thesis and Dissertation Repository

The considerable variation in the spatial distribution of cortical thickness changes has been used to parse heterogeneity in schizophrenia. We aimed to recover a ‘cortical impoverishment’ subgroup with widespread cortical thinning. We applied hierarchical cluster analysis to cortical thickness data of three datasets in different stages of psychosis and studied the cognitive, functional, neurochemical, language and symptom profiles of the observed subgroups. Our consensus-based clustering procedure consistently produced a subgroup characterized by significantly lower cortical thickness. This ‘cortical impoverishment’ subgroup was associated with a higher symptom burden in a clinically stable sample and higher glutamate levels with language impairments in …

Inviting Hallucinatory Percepts During Speech-Listening To Detect Cognitive Changes In Early Psychosis, Ana-Bianca Popa

Electronic Thesis and Dissertation Repository

Treatment outcomes for people with schizophrenia are more favourable if treatment starts early in the course of the disorder. Current detection methods lack specificity and do not make use of cognitive markers. We presented individuals experiencing a first episode of psychosis (FEP) and matched control participants with acoustically degraded meaningful and matched nonsense sentences to examine the degree to which people reported words that were not actually presented. Intrusion errors were counted when reported words were unrelated to words in the original sentence. Intelligibility (measured as words reported correctly) did not differ between groups but intrusion errors were more frequent …

Measuring Brain Serine With Proton Magnetic Resonance Spectroscopy At 3.0 Tesla, Homa Javadzadeh

Electronic Thesis and Dissertation Repository

Proton magnetic resonance spectroscopy (MRS) non-invasively measures regional human brain chemistry in vivo, providing concentration estimates for several metabolites in a pre-selected region of interest. MRS has been applied to investigations of disease-related metabolic and neurochemical alterations in schizophrenia since the early 90’s.

The objective of this research is to implement a metabolite-selective MRS method to quantify endogenous concentrations of human brain serine. Serine is a naturally-occurring amino acid and an important co-modulator of the N-Methyl D-aspartic Acid (NMDA) glutamate receptor. Glutamate abnormalities have been implicated in the pathophysiology of schizophrenia, especially its so-called negative and cognitive symptoms, which can …

Addressing Very Short Stimulus Encoding Times In Modeling Schizophrenia Cognitive Deficit, Colleen D. Cutler

Electronic Thesis and Dissertation Repository

It is well known that encoding times in persons with schizophrenia are longer than those of normal controls. Neufeld and others have argued that this is the consequence of additional subprocesses being executed during the encoding process in the case of schizophrenia. In general they expressed an encoding time as the sum of $k^{\prime}$ independent exponentially-distributed subprocesses, each executed with rate $v$. A troubling consequence of their application of this model to real data was that under some circumstances some individuals appeared to encode instantaneously. This was accommodated in Neufeld et al. by placing a Poisson distribution on …

Beyond Early Intervention, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Antipsychotics And Outcome In Schizophrenia, Amresh Srivastava, Anukant Mital

Psychiatry Presentations

No abstract provided.

Predictors And Characteristics Of Response And Nonresponse: A Ten Year Follow-Up Of First Episode Schizophrenia In Mumbai, Amresh Shrivastava, Nilesh Shah, Megan Johnston, Larry Stitt, Meghana Thakar, Gurusamy Chinnasamy

Psychiatry Presentations

▪ It is not clearly known what predicts good long-term outcome in first episode schizophrenia and what the characteristics are that differentiate patients who do and do not show good response

▪ We attempted to find the characteristics and predictors of good out-come for patients who presented with severe psychopathology and were hospitalized in their first episode psychosis in a tertiary psychiatric hospital in the city of Mumbai

▪ 101 patients of first episode schizophrenia were assessed at hospitalization, and reassessed at ten years

▪ The data was analyzed on 13 outcome parameters for predictors and characteristics of good outcome, …

Do Atypical Antipsychotics Differ In Determining Long-Term Outcome Of First Episode Schizophrenia? A Naturalistic Outcome Study In India, Amresh Srivastava, Nilesh Shah, Megan Johnston, Larry Stitt, Meghana Thakar, Gurusamy Chinnasamy, Anukant Mital

Psychiatry Presentations

Antipsychotic medications form the mainstream of treatment in schizophrenia. These drugs have several short term as well long term advantage. It is not known if atypical antipsychotics have the long-term effect in improving outcome and meeting expectations (1,2,3). The present study examined usage and association of antipsychotics drugs with clinical outcome a long-term naturalistic study.

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Baseline Serum Prolactinin Drug Naïve First Episode Schizophrenia Predicts A Positive Clinical And Social Outcome At Five Years, Post Discharge Follow-Up, Amresh Srivastava, Manoj Tamhane, Meghana Thakar, Yves Bureau, Nilesh Shah

Psychiatry Presentations

Serum prolactinis an indicator of tuberoinfundibulardopamine activity. It is reported to increase in wide variety of mental illnesses. It has close relationship with antipsychotic therapy. However, its relationship with psychopathology and outcome is not clear. Serum prolactinlevel was measured in 30 male and 30 female drug naive patients of schizophrenia. Subsequently, these patients were treated with antipsychotics. The severity of psychopathology at the baseline and subsequent improvement at the end of 3 weeks and 6 weeks was assessed on modified brief psychiatric rating scale (mBPRS). Available to follow up at five years 18 males & 22 females patients were reassessed …

Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

First Episode Is The Best Episode: Lessons And Limitations In Duration Of Untreated Psychosis (Dup) And Outcome In Schizophrenia, Amresh Srivastava, Larry Stitt, Meghana Thakar, Gurusamy Chinnasamy, Nilesh Shah

Psychiatry Presentations

Background: Early intervention in psychosis is an opportunity. Research ahs shown that if any thing community members can do to prevent psychosis is to report early. This has opened newer vistas for understanding the complexity of brain and behaviour in schizophrenia. At the same time it has raised the bar of expectations regarding its correlation to outcome. It finally narrows down to meaningful public campaign for awareness, which will decide success of research to clinics in schizophrenia management. Duration of untreated psychosis (DUP) has emerged as a reliable predictor of outcome and provides credence to development of early intervention services. …

Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava

Psychiatry Presentations

Introduction: cannabis continues to affect mental health. Its abuse is on rise globally. In Canada a rise by 30% in last ten years has been observed in high school students. Interrelationship of cannabis with psychosis and schizophrenia is a complex one. Cannabis is highly comorbid with psychosis, & related to functional disability and outcome. It poses several challenges in understanding causal relationship for comorbidity, underlying neurochemical basis and specifics of service development. Prevalence of Cannabis varies from 20 to 50% early psychosis. Objective of this paper is to review available literature to identify challenges for newer targets of research and …

Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Psychiatry Presentations

No abstract provided.

Outcome In Schizophrenia: The Long-Term Good Outcome In Schizophrenia Is Not Yet Good Enough, Amresh Srivastava, Meghan Thakar

Psychiatry Presentations

The illness of schizophrenia has always been a matter of concern for its nature and extent of outcome particularly for its regional and cultural differences. The concept of outcome has been evolving and this study examines the scenario of good outcome in developing countries.

Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Psychiatry Presentations

No abstract provided.

Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Relapse Prevention In Schizophrenia, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah

Psychiatry Publications

Schizophrenia is a complex neurobehavioral disorder known to be associated with poor outcome. It causes significant disability in patients and burden of care amongst relatives. Outcome in developing countries has been reported to be far better than western world, which has come into scientific scanner recently. Wide gap exists between expectations of outcome amongst patients, relatives, caregivers and professionals, which is possibly because of limitations in measurements tools. Significant number of patients remain marginalized without improvement in social & occupational functioning preventing their integration into mainstream of society despite 'clinically reported good outcome' and significant advancement in treatments. The contemporary …

Schizophrenia: General Findings And Current Status, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava

Psychiatry Presentations

No abstract provided.

Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava

Psychiatry Presentations

No abstract provided.